Scarica l'app Stockscreener
26.36
2.29%
0.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.77
Aprire:
$25.7
Volume 24 ore:
83.03M
Relative Volume:
2.11
Capitalizzazione di mercato:
$149.38B
Reddito:
$59.37B
Utile/perdita netta:
$4.25B
Rapporto P/E:
14.40
EPS:
1.83
Flusso di cassa netto:
$8.23B
1 W Prestazione:
+3.05%
1M Prestazione:
+5.69%
6M Prestazione:
-4.97%
1 anno Prestazione:
-4.60%
Intervallo 1D:
$25.70
$26.49
Intervallo di 1 settimana:
$25.22
$26.52
Portata 52W:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.36 | 149.38B | 59.37B | 4.25B | 8.23B | 0.74 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts - Yahoo Finance
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus.com
Investors Purchase High Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer cost cutting leads to Tampa layoffs - The Business Journals
Pfizer gets FDA accelerated approval for Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment - Marketscreener.com
Pfizer to lay off 62 in Tampa - Business Observer
Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
Pfizer (NYSE:PFE) Trading Up 1.6%What's Next? - MarketBeat
Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Phenobarbital Market CAGR of 5% Trends and Growth Analysis By 2024 to 2031 | Sanofi, Pfizer Inc., Novartis AG, - EIN News
Principal Financial Group Inc. Sells 1,349,308 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts - BioSpace
Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ. - Law360
Why Pfizer (PFE) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Colleagues Celebrate Native American Heritage - Pfizer
Pfizer (NYSE:PFE) Trading 0.4% HigherTime to Buy? - MarketBeat
Liposomal Doxorubicin Market to Witness Massive Growth | Major Giants Pfizer, Ipsen, Johnson & Johnson - openPR
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance? - Investor's Business Daily
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? - Yahoo Finance
PFIZER INC : Gets a Neutral rating from UBS - Marketscreener.com
Stomach Cancer Drugs Market Future Business Opportunities - openPR
Pfizer's SWOT analysis: stock outlook amid pipeline progress and cost cuts - Investing.com
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around? - Yahoo Finance
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis) (NYSE:PFE) - Seeking Alpha
Satellite Images Reveal Russian Military Movements in Syria - Yahoo Finance
Pfizer (NYSE:PFE) Shares Down 0.4% Following Analyst Downgrade - MarketBeat
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call (PFE) - Seeking Alpha
Pfizer eyes 2025 revenue growth despite post-COVID challenges, activist pressure - MM+M Online
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations - Yahoo Finance
Pfizer reiterated at Market Perform by analyst following FY25 guidance - Investing.com Canada
Truist cuts Pfizer shares target, retains buy rating on growth projections - Investing.com
Pfizer: Jefferies confirms its analysis on the stock - Marketscreener.com
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy - Yahoo! Voices
Trending tickers: The latest investor updates on Pfizer, Micron, Nissan, Teva and National Grid - Yahoo Finance UK
Pfizer provides full-year 2025 guidance - The Pharma Letter
Pfizer aims to quell concern about its vaccine business under Trump - Crain's New York Business
Pfizer Sets 2025 Outlook, Confirms 2024 Guidance - Mirage News
Oncology Drugs Market Huge Growth in Future Scope 2024-2031 | - openPR
Epilepsy Drugs Market Detailed In New Research Report 2024 | - openPR
Pfizer Stock Jumps After Reassuring 2025 Guidance - The Wall Street Journal
Medicare Part D Redesign: Pfizer’s Catastrophic Phase Discounts Will Total $1.5bn In 2025 - Citeline News & Insights
Pfizer Confident On Policy Outlook Heading Into Trump Administration - Citeline News & Insights
Pfizer Stock Surges 4% on Reaffirmed Earnings Guidance, Don't Buy Shares Yet - Money Morning
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump: Will 'Knock Out' Pharma Middlemen - Marketscreener.com
Pfizer (NYSE:PFE) Trading Up 4%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Gap UpStill a Buy? - MarketBeat
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
1.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):